☆ 4.4 Article

Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema in Routine Clinical Practice: Results from the 24-Month AURIGA Observational Study

OPHTHALMOLOGY AND THERAPY (2023)

Related references

Note: Only part of the references are listed.

Review Pharmacology & Pharmacy

Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World

Leah Burns et al.

Summary: This article reviews the current global regulatory environment regarding real-world evidence (RWE), including differences in regulatory frameworks, data quality guidance, and study methods guidance across countries. It also highlights opportunities for further development and harmonization.

CLINICAL THERAPEUTICS (2022)

Add to Collection

Review Ophthalmology

Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: A systematic review and meta-analysis

James H. B. Im et al.

Summary: Diabetic macular edema (DME) is a common cause of vision loss in individuals with diabetes. Optical coherence tomography (OCT) is an effective method for accurately diagnosing and detecting DME at an early stage. A meta-analysis was conducted to determine the global prevalence of OCT-diagnosed DME. The analysis included seven studies and found that approximately 5.5% of people with diabetes have DME. There was no significant difference in prevalence between high-income countries and low-to-middle-income countries. These findings highlight the importance of educating physicians and individuals with diabetes about the early detection and treatment of DME using OCT.

SURVEY OF OPHTHALMOLOGY (2022)

Add to Collection

Article Ophthalmology

Evaluation of standard of care intravitreal aflibercept treatment of diabetic macular oedema treatment-naive patients in the UK: DRAKO study 12-month outcomes

Sobha Sivaprasad et al.

Summary: The DRAKO study evaluated the effectiveness of intravitreal aflibercept for the treatment of diabetic macular edema in UK clinical practice, showing that the treatment is able to maintain or improve visual acuity in patients with good baseline visual acuity.

EYE (2022)

Add to Collection

Article Multidisciplinary Sciences

Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema

Jean-Francois Korobelnik et al.

Summary: The APOLLON study evaluated the effectiveness of intravitreal aflibercept (IVT-AFL) treatment for diabetic macular edema (DME) over 24 months in routine clinical practice in France. The study found that treatment-naive patients achieved significant gains in visual acuity, while previously treated patients maintained prior gains.

SCIENTIFIC REPORTS (2022)

Add to Collection

Review Cell Biology

Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications

Jingfa Zhang et al.

Summary: Diabetic retinopathy and diabetic macular edema are major causes of vision loss and blindness in working-age adults, with Vascular endothelial growth factor (VEGF) playing a key role in their pathogenesis. Intravitreal injection of anti-VEGF agents is the main treatment for DME, but not all patients respond well to this therapy.

CELLS (2022)

Add to Collection

Review Ophthalmology

Efficacy and safety of aflibercept therapy for diabetic macular edema: A systematic review and meta-analysis

Sangeetha Santhakumaran et al.

Summary: Aflibercept is a safe and effective therapy option for diabetic macular edema (DME) in the clinical setting, showing better results compared to laser photocoagulation. The evidence regarding comparisons with bevacizumab, ranibizumab, and dexamethasone is mixed and limited.

JOURNAL OF CURRENT OPHTHALMOLOGY (2022)

Add to Collection

Review Ophthalmology

A novel tool to assess the quality of RWE to guide the management of retinal disease

Robert P. Finger et al.

Summary: This paper summarizes the development of a user-friendly tool for assessing the quality of real-world evidence in retinal disease, based on the validated GRACE guidelines. The tool aims to simplify the evaluation and comparison of published evidence in the field, providing guidance on treatment details, outcome measures, study population, and controlling for bias, to support clinical decision-making.

ACTA OPHTHALMOLOGICA (2021)

Add to Collection

Review Ophthalmology

VEGFR1 signaling in retinal angiogenesis and microinflammation

Akiyoshi Uemura et al.

Summary: VEGFR1 and its ligands play important roles in angiogenesis and microinflammatory cascades within the retina, but the mechanisms of their actions remain unclear, the competition for receptor binding and heterodimerization complicates the understanding of their relative contributions.

PROGRESS IN RETINAL AND EYE RESEARCH (2021)

Add to Collection

Article Ophthalmology

Gender-related differences in patients treated with intravitreal anti-vascular endothelial growth factor medication for diabetic macular oedema

Johannes Schiefelbein et al.

EUROPEAN JOURNAL OF OPHTHALMOLOGY (2020)

Add to Collection

Article Ophthalmology

Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study

Jean-Francois Korobelnik et al.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2020)

Add to Collection

Article Ophthalmology

Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy - a systematic approach to identify and characterize data sources

Vincent Daien et al.

BMC OPHTHALMOLOGY (2019)

Add to Collection

Review Ophthalmology

Mechanisms of macular edema: Beyond the surface

Alejandra Daruich et al.

PROGRESS IN RETINAL AND EYE RESEARCH (2018)

Add to Collection

Review Ophthalmology

Diabetic macular edema: Evidence-based management

David J. Browning et al.

INDIAN JOURNAL OF OPHTHALMOLOGY (2018)

Add to Collection

Article Ophthalmology

Intravitreal Aflibercept for Diabetic Macular Edema 148-Week Results from the VISTA and VIVID Studies

Jeffrey S. Heier et al.

OPHTHALMOLOGY (2016)

Add to Collection

Article Ophthalmology

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial

John A. Wells et al.

OPHTHALMOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

John A. Wells et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Ophthalmology

Is it time to confine Snellen charts to the annals of history?

Jan E. Lovie-Kitchin

OPHTHALMIC AND PHYSIOLOGICAL OPTICS (2015)

Add to Collection

Article Ophthalmology

Intravitreal Aflibercept for Diabetic Macular Edema 100-Week Results From the VISTA and VIVID Studies

David M. Brown et al.

OPHTHALMOLOGY (2015)

Add to Collection

Article Ophthalmology

Intravitreal Aflibercept for Diabetic Macular Edema

Jean-Francois Korobelnik et al.

OPHTHALMOLOGY (2014)

Add to Collection

Article Ophthalmology

Reproducibility of Spectral-Domain Optical Coherence Tomography Retinal Thickness Measurements and Conversion to Equivalent Time-Domain Metrics in Diabetic Macular Edema

Susan B. Bressler et al.

JAMA OPHTHALMOLOGY (2014)

Add to Collection

Article Peripheral Vascular Disease

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

Nicholas Papadopoulos et al.

ANGIOGENESIS (2012)

Add to Collection

Article Ophthalmology

NOVEL METHOD FOR ANALYZING SNELLEN VISUAL ACUITY MEASUREMENTS

Ninel Z. Gregori et al.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2010)

Add to Collection

Article Ophthalmology

Responsiveness of NEI VFQ-25 to Changes in Visual Acuity in Neovascular AMD: Validation Studies from Two Phase 3 Clinical Trials

Ivan J. Suner et al.

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2009)

Add to Collection

Article Ophthalmology

Evaluation of minimum clinically meaningful changes in scores on the national eye institute visual function questionnaire (NEI-VFQ) SST report number 19

Paivi H. Miskala et al.

OPHTHALMIC EPIDEMIOLOGY (2007)

Add to Collection

Article Geriatrics & Gerontology

Development and initial validation of the Falls Efficacy Scale-International (FES-I)

L Yardley et al.

AGE AND AGEING (2005)

Add to Collection

Article Ophthalmology

Development of the 25-item National Eye Institute Visual Function Questionnaire

CM Mangione et al.

ARCHIVES OF OPHTHALMOLOGY (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.